IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson’s disease and other neurological conditions
Objective: To summarize clinical experience with incobotulinumtoxinA (INCO) for treating chronic sialorrhea due to Parkinson’s disease (PD), atypical parkinsonism, stroke, or traumatic brain injury in…Evaluation of an Oral Health Questionnaire in Parkinson’s Disease to Facilitate a Multi-disciplinary Approach to improving Care Through Education
Objective: To determine if the oral health questionnaire (OHQ) devised could help to promote good oral hygiene in Parkinson’s disease (PD) while considering the potential…IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC) into…Comparison of Voice, Speech, Swallowing and Drooling Problems in Parkinson’s Disease Patients with Healthy Individuals
Objective: To compare voice, speech, swallowing and drooling problems in Parkinson's disease (PD) patients with healthy individuals (HI) by using objective and subjective methods and…Efficacy of Incobotulinumtoxin/A Treatment for Children/Adolescents with Sialorrhea associated with Neurological Disorders
Objective: The SIPEXI (Sialorrhea Pediatric Xeomin Investigation) study investigated efficacy and safety of intraglandular incobotulinumtoxinA (incoBoNT/A) injections in children/adolescents with sialorrhea associated with neurological disorders…Prevalence, impact, and factors associated with excessive buccal saliva in the COPARK database
Objective: To describe the prevalence of sialorrhea and drooling in Parkinson’s Disease (PD) patients of the COPARK study, to find factors associated to these conditions,…IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: A real-life study
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles into the…GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease
Objective: To assess the 3-month efficacy and safety of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease. Background: A systematic review reported that sialorrhea affects approximately…Parotitis as Adverse Event Following BoNT Injections for Sialorrhea
Objective: Review potential adverse events of parotitis with botulinum toxin injections for sialorrhea. Background: Sialorrhea is a common non-motor symptom of Parkinson’s disease. Botulinum toxin…Atropine as Alternate Therapy for Treatment of Sialorrhea in Parksinson’s Disease
Objective: Evaluating effectiveness of sublingual Atropine 1% ophthalmic solution for treatment of sialorrhea in Parkinson’s disease. Background: Sialorrhea is common non-motor symptom of Parkinson’s disease.…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.